WO2025169168 - EXTRACORPOREAL TRANSFECTION OF IMMUNE EFFECTOR CELLS
National phase entry is expected:
Publication Number
WO/2025/169168
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051381
International Filing Date
10.02.2025
Title **
[English]
EXTRACORPOREAL TRANSFECTION OF IMMUNE EFFECTOR CELLS
[French]
TRANSFECTION EXTRACORPORELLE DE CELLULES EFFECTRICES IMMUNITAIRES
Applicants **
NANOCELL THERAPEUTICS HOLDINGS B.V.
Inventors
LUBELSKI, Jacek
VAN DIEST, Eline
NARAYANAVARI, Suneel
Priority Data
63/551,954
09.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5835 | |
| EPO | Filing, Examination, Granting | 119325 | |
| Japan | Filing, Examination, Granting | 4895 | |
| South Korea | Filing, Examination, Granting | 8599 | |
| USA | Filing, Examination, Granting | 31240 |
Total:
169,894
Contact Us
Abstract[English]
Methods for extracorporeal transfection of an immune effector cell are provided. The method includes contacting blood, or a cell-containing fraction thereof, from a subject with a nanoparticle. The nanoparticle includes a surface-exposed immune effector binding moiety. Furthermore, the nanoparticle includes a nucleic acid encoding a chimeric antigen receptor (CAR) or T-cell receptor (TCR).[French]
L'invention concerne des procédés de transfection extracorporelle d'une cellule d'effecteur immunitaire. Le procédé comprend la mise en contact du sang, ou d'une fraction contenant des cellules de celui-ci, d'un sujet avec une nanoparticule. La nanoparticule contient une fraction de liaison d'effecteur immunitaire exposée en surface. En outre, la nanoparticule contient un acide nucléique codant pour un récepteur antigénique chimérique (CAR) ou un récepteur de lymphocytes T (TCR).